Journal of acquired immune deficiency syndromes (1999) · 2024
Brief Report: Switching to Long-Acting CAB/RPV: Data From an Italian Monocentric Cohort.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Matone Maddalena, Piscaglia Marco, Giacomelli Andrea, Moschese Davide, Capetti Amedeo, Pozza Giacomo, Galli Lucia, Antinori Spinello, Gori Andrea, Rizzardini Giuliano, Cossu Maria Vittoria
Аннотация
BACKGROUND: Cabotegravir (CAB)/rilpivirine (RPV) is the first long-acting injectable (LAI) antiretroviral therapy approved for virologically suppressed adults with HIV-1.
SETTING: Italian single centre cohort.
METHODS: We conducted a retrospective observational study to assess the durability, adherence to the prescribed injection schedule, and reasons for discontinuation of CAB/RPV LAI administered every 8 weeks (Q8W).
RESULTS: One hundred thirty-eight patients were included with a median observation period of 43 weeks [interquartile range (IQR) 34-47 weeks]. Of these, 32 (23.2%) were female, and the median age was 51 years (IQR 40-58 years). Twelve patients (8.7%) discontinued CAB/RPV LAI treatment with a median time to discontinuation of 21 weeks (IQR 12-35 weeks), and 92.8% of the injections occurred within the CAB/RPV LAI schedule. The most common reason for discontinuation was injection-related pain (5/12). No confirmed virological failure occurred during the period of observation with 3 individuals who experienced virological blips.
CONCLUSIONS: Our findings showed that CAB/RPV LAI Q8W is tolerated well in clinical practice, with high adherence to the injection schedule and few discontinuations mainly related to injection site-related pain.
SETTING: Italian single centre cohort.
METHODS: We conducted a retrospective observational study to assess the durability, adherence to the prescribed injection schedule, and reasons for discontinuation of CAB/RPV LAI administered every 8 weeks (Q8W).
RESULTS: One hundred thirty-eight patients were included with a median observation period of 43 weeks [interquartile range (IQR) 34-47 weeks]. Of these, 32 (23.2%) were female, and the median age was 51 years (IQR 40-58 years). Twelve patients (8.7%) discontinued CAB/RPV LAI treatment with a median time to discontinuation of 21 weeks (IQR 12-35 weeks), and 92.8% of the injections occurred within the CAB/RPV LAI schedule. The most common reason for discontinuation was injection-related pain (5/12). No confirmed virological failure occurred during the period of observation with 3 individuals who experienced virological blips.
CONCLUSIONS: Our findings showed that CAB/RPV LAI Q8W is tolerated well in clinical practice, with high adherence to the injection schedule and few discontinuations mainly related to injection site-related pain.